Sobi Supports The Rare Project to Increase Awareness About Rare Diseases

    
Comunicato Precedente

next
Comunicato Successivo

next
CAMBRIDGE, England, (informazione.it - comunicati stampa - arte e cultura)

    

     (Photo: http://photos.prnewswire.com/prnh/20160224/336801 )

The photos can be viewed via the following link: http://www.samebutdifferentcic.org.uk/rare-project

"We are proud to support the raising of awareness of rare disease through collaboration on inspirational initiatives like this one. We aim to place patient value at the heart of what we do. The inspiring stories that patients and families are sharing in 'The Rare Project' only energise us further to strive to do more for rare disease patients," said Neil Dugdale, General Manager for Sobi Ltd.

Sobi Supports The Rare Project to Increase Awareness About Rare Diseases

'The Rare Project' is supported by several UK charities including Rare Disease UK, Genetic Alliance and Climb, (Children Living with Inherited Metabolic Diseases) as well as Big Lottery Wales and Sobi.

About Sobi 
Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi's mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at http://www.sobi.com .


For more information please contact:
UK Media
Neil Dugdale, General Manager UK
T: +44(0)1638722387
E: [email protected]


Media relations    
Oskar Bosson, Head of Communications
T: +46-70-410-71-80
E:[email protected] 

 

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Slide ShowSlide Show
Non disponibili